Reference
·Primary source
BOI Future Medicine approved projects (2020-2024)
~38 projects (2024)
The Board of Investment (BOI) approved approximately 38 Future Medicine S-curve projects in 2024 per BOI annual report, up from 12 in 2020. Cumulative committed capital across 2020-2024 sits at roughly THB 45-50 billion, including biopharmaceutical fill-finish capacity, biosimilar manufacturing (Siam Bioscience, Bio Lab), generic API/excipient backward integration, and medical device assembly. The S-curve Future Medicine and Future Food categories carry the BOI's most generous incentive package including up to 13-year corporate tax holidays and machinery import duty exemption. The pipeline supports Thailand's medical hub ambition framed in successive National Health Plans.
Figure in context
The Board of Investment (BOI) approved approximately 38 Future Medicine S-curve projects in 2024 per BOI annual report, up from 12 in 2020. Cumulative committed capital across 2020-2024 sits at roughly THB 45-50 billion, including biopharmaceutical fill-finish capacity, biosimilar manufacturing (Siam Bioscience, Bio Lab), generic API/excipient backward integration, and medical device assembly. The S-curve Future Medicine and Future Food categories carry the BOI's most generous incentive package including up to 13-year corporate tax holidays and machinery import duty exemption. The pipeline supports Thailand's medical hub ambition framed in successive National Health Plans.
Interpretation notes
What this tells you
The Board of Investment (BOI) approved approximately 38 Future Medicine S-curve projects in 2024 per BOI annual report, up from 12 in 2020. Cumulative committed capital across 2020-2024 sits at roughly THB 45-50 billion, including biopharmaceutical fill-finish capacity, biosimilar manufacturing (Siam Bioscience, Bio Lab), generic API/excipient backward integration, and medical device assembly. The S-curve Future Medicine and Future Food categories carry the BOI's most generous incentive package including up to 13-year corporate tax holidays and machinery import duty exemption. The pipeline supports Thailand's medical hub ambition framed in successive National Health Plans.
What not to do with it
Project count, not capital. Cumulative committed capital across the period roughly THB 45-50 billion.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand pharmaceutical manufacturing factory-gate revenue (2020-2024)
Thai FDA, Pharmaceutical Research and Manufacturers Association of Thailand, Krungsri Research, Bangkok Post pharma coverage
Thailand pharmaceutical generic vs branded mix (2024)
PReMA, IQVIA Thailand, Thai FDA, Government Pharmaceutical Organization
Thailand pharmaceutical manufacturer revenue share (2024)
PReMA, Thai FDA, GPO annual report, Mega Lifesciences, industry estimates
Thailand FDA GMP-certified pharmaceutical facility count (2024)
Thai FDA Drug Control Division, PIC/S accession documentation, PReMA, industry estimates
Siam Bioscience vaccine output capacity (2024)
Siam Bioscience disclosures, PReMA, Bangkok Post pharma coverage, WHO prequalification listing
Thailand pharma facilities with EU GMP cross-certification (2024)
Thai FDA, EudraGMDP database, PReMA, operator disclosures
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.